Clinical Trials Logo

Meal Time clinical trials

View clinical trials related to Meal Time.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03949543 Completed - Feeding Behavior Clinical Trials

The Timing of Main Meal Consumption Effect on Gut Microbiota and Host

TIMC
Start date: October 10, 2017
Phase: N/A
Study type: Interventional

The interplay between diet and the gut microbiota has been implicated in the onset of cardiovascular disease. The gut microbiota displays diurnal rhythms, which may be influenced by meal timing. This study aimed to investigate the effect of main meal consumption timing on the microbiota and the cardiometabolic factors of the host using a cross-over RCT in healthy adults The main outcome measurements will be: a) changes in gut microbiota composition based on 16S rRNA gene amplicon sequencing and shotgun metagenomics, b) changes in bacterial functional capacity) and urinary/faecal metabolomics, c) changes in targeted bacterial metabolites, d)Inflammatory markers The aim of this study is to explore the effect of the timing of main meal consumption on gut microbiota and immune response in healthy adults.

NCT ID: NCT03593343 Completed - Fasting Clinical Trials

Hepatic Glycogen and Fat Oxidation

Start date: January 8, 2019
Phase: N/A
Study type: Interventional

Excessive fat in the liver is associated with impairments in metabolic health. Low levels of DNL and high levels of hepatic fat oxidation are considered to be protective. A decrease in glycogen stores has been causally linked to improved whole body fat oxidation. Also on an organ level, it is suggested that hepatic fat oxidation is stimulated by low hepatic glycogen stores. Next to hepatic fat oxidation, DNL may be influenced by hepatic glycogen stores. Some studies have shown that prolongation of fasting time lowers hepatic glycogen content. It is therefore hypothesized that prolonging fasting time will lower glycogen content and thereby increases fat oxidation and decreases DNL in the liver. To this end, hepatic fat oxidation (plasma marker beta-hydroxybutyrate), de novo lipogenesis, hepatic glycogen content and intrahepatic fat content, will be measured upon a short overnight fast and an extended overnight fast in 13 overweight/obese subjects with hepatic steatosis.